AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...
PharmaTher Provides Update on FDA New Drug Application for Ketamine
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, ...
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...
FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
RiverBender.com2d
Budzinski Introduces Legislation to Increase Competition and Lower Prescription Drug Costs
Congresswoman Nikki Budzinski (IL-13) introduced the Bringing Low-Cost Options and Competition while Keeping Incentives ...
Nasdaq6d
Eton Pharmaceuticals Announces FDA Extension of PDUFA Goal Date for ET-400 New Drug Application
Eton Pharmaceuticals, Inc. announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for ET-400 to May 28, 2025, allowing the agency additional time to review ...